Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma

Area of Science:

• Oncology
• Clinical Trial Management
• Health Disparities

Background:

• Multiple myeloma (MM) disproportionately affects Black and Hispanic/Latino populations in the U.S.
• These demographic groups are significantly underrepresented in clinical trials for MM.
• Addressing these disparities is crucial for equitable cancer care.

Purpose of the Study:

• To identify and discuss actionable strategies for improving diversity and inclusivity in multiple myeloma clinical trials.
• To bring together key stakeholders from across the multiple myeloma research and care ecosystem.
• To overcome documented barriers hindering participation of underrepresented populations.

Main Methods:

• A 1-day workshop sponsored by the Multiple Myeloma Research Foundation.
• Convened 46 experts from government, academia, non-profits, industry, community organizations, and retail pharmacy.
• Focused on identifying specific, tangible steps to enhance clinical trial diversity.

Main Results:

• Discussion centered on practical solutions to improve trial diversity and inclusivity.
• Key strategies proposed include broadening eligibility criteria and reducing participant burdens (financial, logistical).
• Recommendations also covered selecting diverse study sites, implementing implicit bias training, and empowering patients.

Conclusions:

• Multiple myeloma clinical trial diversity requires a multi-faceted, collaborative approach.
• Tangible steps can be implemented to reduce barriers and increase participation of underrepresented groups.
• Empowering patients and addressing systemic issues are vital for equitable MM research and care.